Media center

We provide ongoing updates on our commercial, clinical and financial progress through regular press releases, presentations and webcasts, which can be accessed through the company’s media center.

Press Releases

Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association

Click here to download full press release Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication...

Preliminary Results for the Year Ended 31 December 2018

Click here to download the full 2018 preliminary results statement Oxford, UK – 1 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces...

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Click here to download the full press release – Duaklir® launch planned H2 2019 – – Duaklir® to join Tudorza® in Circassia’s portfolio of US COPD products – Oxford, UK – 1 April 2019: Circassia...

More press releases

In this section

Press releases

Presentations

Webcasts & audio

Image library

Media contacts